Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 30 Breast Neoplasms 23 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Multiple Myeloma 13 Neoplasms 12 Leukemia, Myeloid, Acute 12 Leukemia, Lymphocytic, Chronic, B-Cell 10 Carcinoma, Renal Cell 9 Prostatic Neoplasms 8 Ovarian Neoplasms 8 Neoplasm Metastasis 8 Colorectal Neoplasms 8 Melanoma 7 Lymphoma, Non-Hodgkin 7 Leukemia 7 Recurrence 6 Carcinoma, Hepatocellular 6 Carcinoma 6 Small Cell Lung Carcinoma 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma 5 Fallopian Tube Neoplasms 5 Adenocarcinoma 5 Urinary Bladder Neoplasms 4 Stomach Neoplasms 4 Purpura, Thrombocytopenic, Idiopathic 4 Myelodysplastic Syndromes 4 Lymphoma, Follicular 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Hemophilia A 4

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡